Join NCF for Feb2024. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=DcewKhYm8uY Learn about Carcinoid Heart Disease from Cardiologist Dr. S. Allen Luis, at the Mayo Clinic in Rochester, MN. He will describe the cause and symptoms of carcinoid heart disease and discuss diagnosis, treatment and surveillance. ABOUT DR. ALLEN LUIS Dr. S. Allen Luis, MD, Ph.D, is the Associate Dean for Student and Faculty Affairs at the Mayo Clinic School of Health Sciences and the Associate Chair for Education for the Department of Cardiovascular Diseases. He also serves as Medical Director for the Mayo Clinic School of Health Sciences Echocardiography and Advanced Cardiovascular Sonography Programs. He works in the Carcinoid Heart Disease Clinic, is Co-director of the Pericardial Diseases Clinic and is an Associate Professor of Medicine at Mayo Clinic (Rochester, Minnesota). Dr. Luis is an Associate Editor for Frontiers in Cardiovascular Medicine and a member of the American Journal of Cardiology Editorial Board. He serves on the Board of Directors for the American College of Cardiology (Minnesota Chapter) and the Committee on Accreditation for Advanced Cardiovascular Sonography. Dr. Luis’ principal clinical and research interests include the use of echocardiography and multimodality cardiac imaging in the investigation, management and prognostication of patients with carcinoid heart disease. His other clinical and research interests include cardio-oncology, valvular heart disease and pericardial diseases. THANKS TO OUR SPONSORS The information provided is for educational purposes only and does not substitute for medical advice. Talk to your medical team if you have any questions or concerns about your individual care and treatment. The opinions expressed in this program are those of the speakers and do not represent the opinion of LACNETS.

Join NCF for NCD2024. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page WATCH THE RECORDING Celebrate NET Cancer Day at the LACNETS NET Cancer Day Symposium in Santa Monica, California on Saturday, November 9th from 8:30 am - 3:30 pm. ABOUT Hear presentations from local NET experts and stories from those in the neuroendocrine cancer community. Learn about the latest in surgery, medical treatments, PRRT, symptom management, and clinical trials. Ask questions during the live question and answer sessions. Find out how you can spread awareness about neuroendocrine cancer. Show how you live well with Neuroendocrine Cancer in our "Show & Tell" Video Slideshow (will be played during our reception). Post-Event Ice Cream Social There is no cost to attend. This event is made possible by the generosity of donors and sponsors. This event will not be broadcast. LOCATION Santa Monica Bay Woman's Club 1210 4th St, Santa Monica, CA 90401 Parking will be fully validated at SP+ Parking Garage Structure 1 at 1234 4th St, Santa Monica, CA. AGENDA *Subject to change. Please check back closer to the event for the most accurate agenda. Time Topic Speaker 8:30 - 9 AM Registration & Breakfast 9 - 9:10 AM Welcome LACNETS Team 9:10 - 9:20 AM A NET Impact Story A NET Patient 9:20 - 9:35 AM A NET Surgeon's Perspective on What to Ask Your Surgeon & How to Prepare for Surgery Alexandra Gangi, MD, Surgical Oncologist, Cedars-Sinai 9:35 - 9:50 AM Alpha vs Beta PRRT: Which is for me? Martin Auerbach, MD, Nuclear Medicine, UCLA 9:50 - 10:20 AM Q&A Alexandra Gangi, MD, Surgical Oncologist, Cedars-Sinai & Martin Auerbach, MD, Nuclear Medicine, UCLA 10:20 - 10:50 AM Break 10:50 - 10:55 AM A NET Impact Story A NET Caregiver 10:55 - 11:15 AM The Latest in NET Medical Therapies Andrew Hendifar, MD, Medical Oncologist, Cedars-Sinai 11:15 - 11:35 AM The Endocrine in Neuroendocrine Run Yu, MD, Endocrinologist, UCLA 11:35 - 11:50 AM Liver Directed Therapy for Neuroendocrine Liver Tumors H. Gabriel Lipshutz MD, Interventional Radiologist, Cedars-Sinai 11:50 AM - 12:30 PM Q&A All Faculty (Moderated by Lisa Yen) 12:30 - 1:30 PM Lunch & Networking 1:30 - 2:05 PM The Future of NETs: Evolving Treatments & Clinical Trials Jaydira Del Rivero, MD, Medical Oncologist, Endocrinologist, National Cancer Institute, National Institutes of Health 2:05 - 2:25 PM Spreading Awareness Globally: INCA's Think NENs Stephanie Alband, INCA President & PPA Executive Director 2:25 - 2:35 PM Let's Talk About NETs: How YOU Can Spread Awareness Heather Davis, LACNETS Associate Director of Advocacy & Outreach 2:35 - 3:00 PM Music Heals Drum Healing with John Fitzgerald 3:05 - 3:15 PM Closing LACNETS Team 3:15 - 4:30 PM Networking Reception with Show & Tell Slideshow MODERATORS : Andrew Hendifar, MD, & Lisa Yen, Director of Programs and Outreach SPEAKERS: ALEXANDRA GANGI, MD Surgical Oncologist, Cedars-Sinai Medical Center Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. ANDREW HENDIFAR, MD Medical Oncologist, Cedars-Sinai Medical Center The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. MARTIN AUERBACH, MD Nuclear Medicine, UCLA Dr. Allen-Auerbach is the Medical Director of UCLA Nuclear Medicine and Clinical Professor in Nuclear Medicine, Division of Pharmacology, at the David Geffen School of Medicine at UCLA. Apart from serving as attending physician in Nuclear Medicine, active research includes clinical studies investigating the role of molecular imaging with PET/CT to gain insights into malignant disease processes and as well as applications of Nuclear Medicine for the treatment of cancer. RUN YU, MD, PhD Endocrinologist, UCLA Run Yu, MD, PhD, received his MD degree from Peking Union Medical College in Beijing and his PhD degree in pharmacology from University of Rochester in New York. Dr. Yu completed an endocrine research fellowship, an internal medicine residency, and a clinical endocrinology fellowship at Cedars-Sinai Medical Center. Dr. Yu’s clinical and research interests include diabetes, thyroid, and endocrine tumors and syndromes. Dr. Yu enjoys describing novel clinical findings in endocrinology. H. GABRIEL LIPSHUTZ, MD Interventional Radiologist Cedars-Sinai Medical Center H. Gabriel Lipshutz, MD is a board-certified, fellowship-trained vascular and interventional radiologist with the Cedars-Sinai S. Mark Taper Foundation Imaging Center. Dr. Lipshutz performs all peripheral endovascular and interventional procedures including embolizations and minimally invasive oncological treatments (chemoembolization, Y-90 radioembolization, RFA, cryoablation, microwave ablation, and irreversible electroporation (IRE). His responsibilities include consultation and treatment of outpatients and inpatients, including the evaluation of patients in the IR outpatient clinic. After earning his bachelor's degree from Wesleyan University, Dr. Lipshutz earned his medical degree from the University of California, San Francisco. He completed his internship in internal medicine at the University of Washington, his radiology residency at the Oregon Health and Sciences University, and his fellowship in interventional radiology at UCLA. JAYDIRA DEL RIVERO, MD Medical Oncologist & Endocrinologist National Cancer Institute, National Institutes of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. STEPHANIE ALBAND, MSBA Board President, INCA Executive Director, The Pheo Para Alliance Stephanie Alband, MSBA, joined Pheo Para Alliance in March of 2019. She has over 20 years of experience in the nonprofit industry, with ten years working exclusively for rare disease organizations, including the Huntington’s Disease Society of America and Angioma Alliance. Her experience with her daughter’s rare cancer has helped her better understand and successfully navigate the unique challenges faced by the rare disease community. She currently serves as the President for the International Neuroendocrine Cancer Alliance (INCA) and previously served as Communications Chair and a Member of the Board of Directors. JOHN FITZGERALD Drum Circle Facilitator & Coach Rhythm With a Purpose Before he fell in love with the transformational impact of coaching, and rhythm facilitation, John spent decades as a degreed percussionist performing jazz and classical music, and the amazing music of cultures from around the world. Rhythms, cycles, and improvisation have always been central to his joy and passion, the spontaneous personal expression that is such a vital part of all living cultures, and indeed, all our lives. As the Manager of Recreational Music Activities for Remo Inc., for 23 years, he created relationships with organizations and individuals, educating and advocating for the use of music for wellbeing in every imaginable population through a global network of partnerships, facilitators, and Remo’s distributor network. Presentations, training, and facilitated experiential activities at conferences and symposia were a central part of his work at Remo, and his passion as well. In addition to one on one work with individuals and organizational leaders, John designed and facilitated team-building, communication and leadership workshops for over 20 years. If you are newly diagnosed, or need a refresher on NET terms and basics, we encourage you to watch Dr. Aman Chauhan’s presentation “NETS 101: Overview of NET Terms & Concepts " or Dr. Chandrasekharan’s presentation “Understanding NET Diagnosis.” The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by LACNETS or the sponsors of this program. LACNETS does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

Lu-177 DOTATATE + Triapine in GEP-NETs << Back Phase 2 Trial: Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors DRUG/TREATMENT: LUTATHERA (Lu-177) + Triapine CLINICALTRIALS.GOV IDENTIFIER: NCT05724108 PHASE: 2 STATUS: Recruiting SPONSOR: National Cancer Institute (NCI) https://www.youtube.com/watch?v=ptDSlj3Neao June 2024: Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine study https://www.youtube.com/watch?v=rK0NSdorBnk April 2023: Dr. Aman Chauhan discusses Phase 2 LUTATHERA (Lu-177) + Triapine study DESCRIPTION: This phase II trial compares the effect of adding triapine to lutetium Lu 177 dotatate versus lutetium Lu 177 dotatate alone (standard therapy) in shrinking tumors or slowing tumor growth in patients with neuroendocrine tumors that have spread from where they first started (primary site) to other places in the body (metastatic). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for deoxyribonucleic acid synthesis and cell growth. Lutetium Lu 177 dotatate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177 dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving triapine in combination with lutetium Lu 177 dotatate may be more effective at shrinking tumors or slowing tumor growth in patients with metastatic neuroendocrine tumors than the standard therapy of lutetium Lu 177 dotatate alone. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT/Principal Investigator: Aman Chauhan, MD EMAIL: axc3268@med.miami.edu RELATED RESOURCES Clinical Trials Using Lutetium Lu 177 Dotatate - NCI Dr. Chauhan's presentation slides can be downloaded here: Dr. Chauhan Presentation on Lu-177 DOTATATE + Triapine Trial .pptx Download PPTX • 16.18MB 2023 NANETS Abstract shows the combination of Triapine and Lu-177 DOTATATE was safe with preliminary efficacy signals.

Join NCF for Feb2025. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=wgEoFAQ7lp8 ABOUT Learn the latest in genetics and genomics for neuroendocrine cancers from medical oncologist Dr. Kimberly Perez from Dana Farber Cancer Institute (DFCI) in Boston, Massachusetts. Dr. Perez has expertise in hereditary cancer syndromes and deciphers the topics of genetics and genomics. ABOUT DR. PEREZ Kim Perez, MD Medical Oncologist D ana Farber Cancer Institute (DFCI) Dr. Kimberly Perez, MD is a member of the Dana-Farber Cancer Institute/Harvard Cancer Center Gastrointestinal Oncology and Cancer Genetics and Prevention disease centers. She is a Senior Physician in Medical Oncology at Dana-Farber Cancer Institute, an Associate Physician in Medical Oncology at Brigham and Women’s Hospital, co-Director of the DFCI Gastrointestinal Clinical Trials program, and an Assistant Professor of Medicine at Harvard Medical School. She received her undergraduate training at Georgetown University in Washington DC and received her medical doctorate from George Washington University in Washington DC. She completed her residency and fellowship training at Rhode Island Hospital in 2010. After completing her fellowship, she joined the medical faculty at Warren Alpert School of Medicine at Brown University and served as a Gastrointestinal Oncologist at the Comprehensive Cancer Center at Rhode Island Hospital. She joined the faculty at the Dana-Farber Cancer Institute in 2015 as a medical oncology physician-scientist who provides patient care and conducts clinical research of novel therapies for patients diagnosed with gastrointestinal cancers and inherited cancer syndromes. Since she joined the faculty, she was designated a Hale Family Center for Pancreatic Cancer Research Clinical Investigator and has developed and led investigator-initiated bench to clinic multi-institutional clinical trials for patients with pancreatic adenocarcinoma. Within the Neuroendocrine and Carcinoid program, she has led multi-institutional clinical trials, translational efforts, and served and led national therapeutic guideline efforts. Dr. Perez is a medical oncology physician-scientist who provides patient care and conducts clinical research of novel therapies for patients diagnosed with gastrointestinal cancers and associated hereditary cancer syndromes. Since she joined the faculty at Harvard Medical School and the Dana-Farber Cancer Institute in 2015, she has developed and led investigator-initiated clinical trials investigating novel therapies for patients with pancreatic adenocarcinoma and neuroendocrine tumors. The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by LACNETS or the sponsors of this program. LACNETS does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.

Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) << Back Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) CLINICALTRIALS.GOV IDENTIFIER: NCT05997056 DRUG/TREATMENT: IV PHASE: 2 STATUS: Recruiting SPONSOR: Aadi Bioscience, Inc. DESCRIPTION: https://www.youtube.com/watch?v=DbA55lS1dhk Dr. Scott Paulson Discusses the Nab-sirolimus Trial This is a prospective phase 2 single arm, open-label, multi-institutional study to determine the efficacy and safety prospective of nab-sirolimus and patients with functional or non-functional, well-differentiated, locally advanced unresectable in metastatic NETs of the GI tract, lung, or pancreas. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT/Principal Investigator: Aadi Bioscience Medical Information EMAIL: MedInfo@aadibio.com PHONE: 1-888-246-2234 Locations: Recruiting: United States at Texas Oncology in Dallas, Texas 75246 Contact: Christine Terraciano at christine.terraciano@usoncology.com Principal Investigator: Scott Paulson, MD Recruiting: United States at Hoag Memorial Hospital Presbyterian in Newport Beach, California 92663 Contact: Jason Ledesma at jason.ledesma@hoag.org Principal investigator: Michael Demeure, MD Not Yet Recruiting: United States, Denver, Colorado 80218

<< Go back to the Podcast page EPISODE 37: SUPPORTIVE ONCOLOGY FOR NEUROENDOCRINE CANCER Download a Transcript of this Episode >>> ABOUT THIS EPISODE What is supportive care or supportive oncology? What is cancer-related distress? How might NET patients benefit from supportive care? Yale oncologist Dr. Maryam Lustberg suggests strategies to manage cancer-related fatigue, diarrhea, nausea, mouth sores, peripheral neuropathy, distress, anxiety, and anxiety. She also addresses considerations for fertility and sexual health. MEET DR. MARYAM LUSTBERG Dr. Maryam Lustberg is an American breast oncologist. She is the Director of The Breast Center at Smilow Cancer Hospital and Chief of Breast Medical Oncology at Yale Cancer Center. Dr. Lustberg previously served as the Medical Director of Cancer Supportive Care Services at Ohio State’s Comprehensive Cancer Center. She is the Immediate Past President of the Multinational Association of Supportive Care in Cancer. She is also an Associate Editor for the Journal of Cancer Survivorship. TOP TEN QUESTIONS ABOUT SUPPORTIVE CARE: What is supportive care in cancer (or supportive oncology)? What is survivorship? How do these concepts apply to the NET community? What is the 1st step for patients to get supportive care? What are the most common treated-related adverse events or side effects? What are risk factors for them? (Will all patients experience all potential side effects?) What causes cancer-related fatigue (CRF)? What are some strategies to manage cancer-related fatigue? What are some strategies to manage diarrhea? What are some strategies to manage nausea? What are some strategies to manage mouth sores? What is peripheral neuropathy? When do patients experience it and what can be done to prevent it? What should patients understand about sexual health and fertility? How can psychosocial needs such as distress, anxiety, and depression be addressed and supported? RESOURCES READ Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship Survivorship Care for People Affected by Advanced or Metastatic Cancer: MASCC-ASCO Standards and Practice Recommendations Supportive Care: Low Cost, High Value Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology–ASCO Guideline LISTEN LACNETS Podcast Episode 35: "NEN Treatments: Focus on Chemotherapy" LACNETS Podcast Episode 18: Mental Health & NETs LACNETS Podcast Episode 15: Psycho-Oncology OTHER RESOURCES LACNETS Nutrition Resources LACNETS Wellness Resources including meditation & yoga DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

<< Go back to the Podcast page EPISODE 20: GASTRIC NET, GASTRINOMAS & ZOLLINGER-ELLISON SYNDROME (ZES) Download a Transcript of this Episode >> ABOUT THIS EPISODE Gastroenterologist and Neuroendocrinologist Dr. David C. Metz discusses important concepts in Gastric NET, Gastrinomas and Zollinger-Ellison Syndrome, including detection, treatments, associated risks and monitoring. He also lends valuable insight on ulcers, MEN and proton pump inhibitors. MEET DR. DAVID C. METZ After earning his MD from the University of the Witwatersrand's Medical School, Dr. Metz was a resident at both the Albert Einstein Medical Center and the Johannesburg General Hospital. He went on to complete fellowships at Georgetown University Hospital as well as the National Institutes of Health. Arriving at Penn Medicine in 1993, David Metz, MD, held a variety of leadership roles within the Department of Gastroenterology, including Co-Directorship of the Neuroendocrine Tumor Center and Penn NET Treatment Program. Dr. Metz was previously a staff fellow at the National Institutes of Health, where he performed basic research in pancreatic acinar cell secretion and clinical research in Zollinger-Ellison syndrome. While at Penn Medicine, he served as Chair of the North American Neuroendocrine Tumor Society (NANETS), as a member of the Liaison Committee for Recertification of the American Board of Internal Medicine (American Gastroenterological Association representative), and on the Food and Drug Administration Gastrointestinal Drugs Advisory Committee, among other positions. Dr. Metz's clinical interests at Penn included Zollinger-Ellison syndrome and other acid-peptic conditions, Helicobacter pylori infection, non-steroidal anti-inflammatory drug gastropathy and the diagnosis and management of patients with functional and non-functional neuroendocrine tumors of the pancreas and alimentary tract. An investigator for a series of prominent clinical trials in all of these areas, Dr. Metz has published more than 200 articles on topics of clinical interest and research. He retired in July 2021 after 28 years at Penn Medicine. In 2021 Dr. Metz received the NANETS Lifetime Achievement Award that honors an individual who, over the course of their career, has provided outstanding contributions to neuroendocrine disease management through research, clinical practice or educational initiatives, as well as exceptional leadership in NANETS and dedication to its mission. TOP 10 QUESTIONS 1. What is Gastric NET? How is it found? What are the symptoms? How does it differ from “stomach cancer” or other types of NETs? 2. How is Gastric NET treated and how is it monitored? 3. What is a Gastrinoma? How and where is it found? Are Gastrinomas and Gastric NET the same thing? 4. How is a Gastrinoma treated? 5. How is a Gastrinoma monitored? How often do you recommend Endoscopies or Gastrin level lab testing? Does a high Gastrin level mean someone has a Gastrinoma or are there other causes? Can you have a high Gastrin level without having a gastrinoma? 6. What is Zollinger-Ellison Syndrome? How is it found? What are the common symptoms from ZES/functioning Gastrinomas? 7. How is Zollinger-Ellison Syndrome treated? How is Zollinger-Ellison Syndrome monitored? Does ZES put you at risk for other conditions/complications? 8. What is a common Proton Pump Inhibitor dose for someone with ZES? Is there a danger in taking PPIs for a long time or in high doses? 9. I’ve been told I have an ulcer? Am I at risk for cancer? 10. What are advances for gastric nets, gastrinomas or Z-E syndrome that we should be aware of or excited about? *Bonus question: What last words of hope would you like to leave the NET community with? RESOURCES https://www.youtube.com/watch?v=dVY3Ws3qm0s Patient Story: Zollinger-Ellison Syndrome and Gastrinoma Shaunie shares her experience living with Zollinger-Ellison syndrome and a functioning gastrinoma of the pancreas. READ Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing Diagnosis of the Zollinger–Ellison Syndrome Gastric Neuroendocrine Tumors (Carcinoids) Neuroendocrine Tumors: Reappraisal of Type in Predicting Outcome DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

ALPHAMEDIX: Alpha PRRT with Pb-212 DOTAMTATE in NETs << Back ALPHAMEDIX - Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients CLINICALTRIALS.GOV IDENTIFIER: NCT05153772 DRUG/TREATMENT: AlphaMedix 212Pb-DOTAMTATE PHASE: 2 STATUS: Recruiting SPONSOR: Radiomedix, Inc. COLLABORATOR: Orano Med LLC https://www.youtube.com/watch?v=HECT9t4V0Ho Dr. Ebrahim Delpassand Discusses the AlphaMedix Trial (May 9, 2023) https://www.youtube.com/watch?v=3sDMIlPbepY Dr. Heloisa Soares Discusses the AlphaMedix Trial (March 10, 2023) UPDATE October 8, 2025: Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors Sanofi reported that its experimental drug AlphaMedix™ (²¹²Pb-DOTAMTATE) met all its main goals in a phase 2 clinical trial, showing real benefits in people with certain gastro-pancreatic neuroendocrine tumors, whether or not they have had prior radiation treatment. The drug was generally well tolerated, and these results will inform future talks with regulators as Sanofi works toward potential approval. Read the full press release >>> DESCRIPTION: Radiomedix is sponsoring a multicenter Phase 2 study of 212Pb-DOTAMTATE enrolling adult subjects with positive somatostatin positive neuroendocrine tumors with no prior history of peptide receptor radionuclide therapy (PRRT naive). In this open-label, multicenter, single-arm Phase 2 study, adult subjects with histologically confirmed NETs and positive somatostatin analog imaging, with no prior PRRT (PRRT naive) will be enrolled to receive 212Pb-DOTAMTATE. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Susan Cork EMAIL: scork@exceldiagnostics.com PHONE: 713-341-3203

<< Go back to the Podcast page EPISODE 9: PRRT (PART II) Download a Transcript of this Episode >> Listen to Episode 8: PRRT (Part One) with Administrative Nurse Lindy Gardner of UCLA Health >> Listen to Episode 10: PRRT (Part Three) with Josh Mailman >> ABOUT THIS EPISODE Who is eligible for PRRT? What are the side effects? Should somatostatin analogues be continued? Can PRRT be repeated when there is disease progression? NET expert and Nuclear Medicine Physician Dr. Martin Auerbach of UCLA Health answers 10 common questions about the decision-making process of PRRT. Dr. Auerbach addresses how to manage side effects, carcinoid crisis, labs, and post-PRRT imaging. MEET DR. MARTIN AUERBACH Dr. Auerbach is the Director of Nuclear Medicine at the Westwood and Santa Monica UCLA Hospitals, and Associate Professor in Nuclear Medicine, Division of Pharmacology, at the David Geffen School of Medicine at UCLA. Apart from serving as attending physician in Nuclear Medicine at the UCLA Santa Monica and Westwood Hospital, active research includes clinical studies investigating the role of molecular imaging with PET/CT to gain insights into malignant disease processes, and monitoring of cancer treatment. TOP 10 PRRT QUESTIONS 1. Who is eligible for PRRT? When considering PRRT, is there a minimum or maximum tumor size? What is the effect if a patient receives half the planned dose or a delay in receiving a dose due to low counts? 2. How do you decide on doses of radioactive agents in PRRT? Do they consider the individual’s weight or does everyone get the same dose? 3. What are the side effects of PRRT and how are they managed? 4. Do you continue SSA with PRRT and if so when should one receive it? 5. Can people have carcinoid crisis with PRRT? If so, how is this treated? 6. When or how often are labs done? Which labs and what are you looking for? 7. When do you do imaging? Which imaging to you do? 8. When would you expect to see a response with PRRT and what is the statistics about the shrinkage or response that is expected? 9. For those who have received 4 doses of Luthatera, what happens if/when there is progression, can PRRT be repeated? Can people have more than 4 doses of Lutathera? 10. What is the difference between alpha and beta PRRT? How would you decide between the alpha or beta PRRT? ADDITIONAL RESOURCES Read the LACNETS Blog Post "These Four Letters: PRRT" >> Click here for additional PRRT Resources >> DISCLAIMER LACNETS Podcasts are created for educational purposes only and do not substitute for medical advice. The views shared in this Podcast are the personal opinions of the experts and do not necessarily reflect the views of LACNETS. Please contact your medical team with questions or concerns about your individual care or treatment. THANK YOU TO OUR SPONSORS

Join NCF for Mar2025. Explore event details, dates, times, and discover opportunities to connect, learn, and get involved. < Back to the upcoming events page https://www.youtube.com/watch?v=Ton887q1R6s Download the Transcript Here >>> Download the Presentation Slides Here >>> ABOUT Learn about PRRT from UCLA's Lead PRRT Nurse Linda Gardner. She addresses common questions about what to expect before, during, and after the treatment, as well as concerns about radiation safety. ABOUT LINDA GARDNER, MSN, RN, VA-BC LINDA (LINDY) GARDNER, MSN, RN, VA-BC Lead Nurse, Nuclear Medicine UCLA Health Lindy has over two decades of Interventional Radiology experience prior to transitioning over to Nuclear Medicine in March of 2017. She obtained her RN qualification in 1993 from John Moores University of Liverpool, (LJMU) United Kingdom, she is a graduate from the University Of Dundee, Scotland where she received her Bachelors, and Master’s of Science in Nursing. In her Nuclear Medicine role Lindy is the lead nurse for the Peptide Receptor Radionuclide Therapy (PRRT) program, from the expanded access program (EAP) through to the FDA approved commercial program. She has presented this program to a national and international audience; her skills are utilized as an expert liaison for institutions commencing the PRRT program, focusing on the patient experience, education, and therapy administration. Lindy is the nursing pillar lead for The International Center for Precision Oncology foundation (ICPO), with her focus on education, support and navigation for the NET patient journey. She is also the lead nurse for Radioligand Therapy (RLT) for prostate cancer within Theranostics at UCLA, covering both clinical application and research. Lindy is a member of the Association for Radiologic and Imaging Nursing (ARIN), and the Association for Vascular Access (AVA), holding her board certification in vascular access (VACC). She serves as a member of the Neuroendocrine Cancer Foundation Medical Advisory Committee and The Healing NET Scientific Advisory Committee. The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

COMPOSE: PRRT with Lu-177 EDOTREOTIDE versus “Standard of Care” in Well-Differentiated Aggressive G2 & G3 GEP-NETs << Back ITM (COMPOSE) Phase III Clinical Trial: 177 LU-EDOTREOTIDE VS. Best Standard of Care in Well-Differentiated Aggressive G2 & G3 GEP-NETs CLINICALTRIALS.GOV IDENTIFIER: NCT04919226 DRUG/TREATMENT: 177Lu-Edotreotide PRRT (Peptide Receptor Radionuclide Therapy) PRRT versus CAPTEM (Capecitabine and Temozolomide), Everolimus or FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin) PHASE: 3 STATUS: Recruiting SPONSOR: ITM https://www.youtube.com/watch?v=r1hmEzrooxE Dr. Heloisa Soares Discusses COMPOSE: PRRT -LU-177 EDOTREOTIDE https://www.youtube.com/watch?v=w9kA8_gmVfM Dr. Will Pegna Discusses COMPOSE: PRRT - LU-177 EDOTREOTIDE Starting at 9:04 UPDATE (March 2025) https://www.youtube.com/watch?v=H0H1RNwIwV0 The Neuroendocrine Cancer Foundation @NCFCancer (previously @LACNETS) interviews Mayo Clinic Medical Oncologist and #NetCancer expert Dr. Thor Halfdanarson at the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland (March 5-7, 2025). Dr. Halfdanarson shares the breaking news of positive results from ITM’s phase 3 COMPETE trial, the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus). DESCRIPTION: ITM is sponsoring “COMPOSE,” an international phase III clinical study to evaluate the efficacy, safety and impact on quality of life of Targeted Radionuclide Therapy (PRRT) with no-carrier-added lutetium-177-edotreotide (n.c.a. 177Lu-edotreotide) compared to a standard therapy with either CAPTEM or everolimus or FOLFOX, in patients with well-differentiated advanced Grade 2 and Grade 3, somatostatin receptor-positive (SSTR+) neuroendocrine tumors of gastroenteric or pancreatic origin (G2 and G3 GEP-NETs). The study is being conducted predominantly in Europe, North America, India and Australia, in approximately 10 countries and 40 sites. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Dr. Nicolas Schneider or Amanda Rotger at ITM EMAIL: info-solucin@itm-radiopharma.com

SORENTO™: Subcutaneous Octreotide for GEP-NETs (CAM2029) << Back SORENTO ™ - A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NETs CLINICALTRIALS.GOV IDENTIFIER: NCT05050942 DRUG/TREATMENT: CAM2029, octreotide LAR, lanreotide ATG PHASE: 3 STATUS: Recruiting SPONSOR: Camurus AB https://www.youtube.com/watch?v=9lKvu6-J4-g Dr. Simron Singh Discusses the SORENTO™ Trial DESCRIPTION: Camurus is sponsoring a phase 3 study to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029. For more information on eligibility criteria, trial locations, study details, etc., go to ClinicalTrials.gov to view this trial here. CONTACT: Camurus AB EMAIL: medicalinfo@camurus.com PHONE: +46 46 286 57 30 Principal Investigator: Simron Singh, MD, MPH Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada